EMERYVILLE, Calif. & BRISBANE, Australia--(BUSINESS WIRE)--Peplin, Inc. (ASX:PLI) today announced financial results for the year ended 30 June 2009, reporting a US$17.7 million cash balance. Peplin will use these funds to complete Phase 3 clinical trials for its lead product, PEP005 (ingenol mebutate) Gel for actinic (solar) keratosis (AK). The company is confident it will have access to sufficient working capital to fund operations through its planned New Drug Application (NDA) filing with the Food and Drug Administration (FDA) in mid-2010.
